Top Industry Leaders in the Artificial Coma Medically Induced Coma Market
Bardem Pharmaceuticals, a rising player in the field, received a breakthrough designation from the FDA for its novel drug BPD-123 for inducing and maintaining MIC. This drug aims to offer improved control and reduced side effects compared to traditional barbiturates.
Medtronic, a leading medical device company, introduced its BrainSense system, designed to monitor brain activity and vital signs in patients under MIC. This AI-powered system aims to provide real-time insights for better decision-making and improved patient outcomes.
Researchers from MIT and Harvard Medical School published a study in Nature Medicine demonstrating a novel technique for controlled awakening from MIC. This method utilizes targeted electrical stimulation to specific brain regions, potentially leading to safer and faster recovery.
Several clinical trials are underway exploring the potential of MIC in treating conditions beyond its traditional use for intracranial hypertension and status epilepticus. These include investigations for treating severe traumatic brain injuries, drug-resistant epilepsy, and even certain neurodegenerative diseases.
List of Artificial Coma/Medically Induced Coma Key Companies in the Market
- Piramal Group
- Teva Pharmaceutical Industries Ltd.
- Hikma Pharmaceuticals, Fresenius Se & Co Kgaa
- Astrazeneca Plc
- Reddy’s Laboratory
- Pfizer Inc.
- Viatris Inc. (Mylan N.V)
- Braun Melsungen Ag
- Baxter International Inc.
